WPD Pharmaceuticals

WPD has eight new drug candidates, four of which are in clinical development and the other four in preclinical development. These drug candidates have been studied at institutions such as MD Anderson Cancer Center, Mayo Clinic, and Emory University. WPD is currently collaborating with Wake Forest University as well as leading hospitals and academic centers in Poland.In addition to $60 million in direct investment, more than $29 million in grant funding (totaling $89 million) has been utilized to develop WPD's robust drug development pipeline, focusing on melanoma, brain cancer, leukemia, and pancreatic cancer. Notably, these funds do not include the recent $14 million grant awarded to WPD Pharmaceuticals by Poland's National Center for Research and Development.